ライフサイエンスコーパス: thrombocytopenia

1 n naturally aged mice without causing severe thrombocytopenia.

2 b and Ab-induced hemolytic anemia and immune thrombocytopenia.

3 ransfusion is common in dengue patients with thrombocytopenia.

4 which immunomodulatory drugs (IMiDs) induce thrombocytopenia.

5 atory abnormalities including leukopenia and thrombocytopenia.

6 or pharmacologic inhibition of MCs reversed thrombocytopenia.

7 rough" of clinical HIT with manifestation of thrombocytopenia.

8 poietic stem and progenitor cells (HSPCs) in thrombocytopenia.

9 le for disorders such as neonatal alloimmune thrombocytopenia.

10 ight its potential as therapeutic target for Thrombocytopenia.

11 to prevent bleeding in preterm infants with thrombocytopenia.

12 transcription factor-encoding gene IKZF5 and thrombocytopenia.

13 NCT01030211.Dengue fever commonly results in thrombocytopenia.

14 on of autoimmune hemolytic anemia and immune thrombocytopenia.

15 rrecting the underlying immunodeficiency and thrombocytopenia.

16 ALE have not previously been associated with thrombocytopenia.

17 oResource, including 233 cases with isolated thrombocytopenia.

18 ntral to the pathogenesis of heparin-induced thrombocytopenia.

19 sence of Scl and Lyl1 mutations in inherited thrombocytopenia.

20 e events in both groups were neutropenia and thrombocytopenia.

21 ve not been observed as a cause of inherited thrombocytopenia.

22 rapeutic agents, without causing appreciable thrombocytopenia.

23 2, and many other genes that cause inherited thrombocytopenia.

24 or anemia, neutropenia, lymphocytopenia, and thrombocytopenia.

25 transfusions in preterm neonates with severe thrombocytopenia.

26 obulin for perioperative treatment of immune thrombocytopenia.

27 creased IL-1beta and IL-6 levels, anemia and thrombocytopenia.

28 g and rapid haematocrit rise concurrent with thrombocytopenia.

29 ade 3 neutropenia, and 1 patient had grade 4 thrombocytopenia.

30 there were no cases of severe neutropenia or thrombocytopenia.

31 23%]), neutropenia (3 [4%] vs 13 [16%]), and thrombocytopenia (1 [1%] vs 11 [14%]).

32 uth (66%), transient G1-2 nausea (48%), G3-4 thrombocytopenia (10%) and G3 anemia (10%).

33 h (66%), transient G1-G2 nausea (48%), G3-G4 thrombocytopenia (10%), and G3 anemia (10%).

34 ssibly related included neutropenia (15.9%), thrombocytopenia (11.1%), and pneumonia (3.2%).

35 4.8%), diarrhea (14.7%), anemia (14.7%), and thrombocytopenia (11.6%).

36 ia (16 [41%] of 39), neutropenia (12 [31%]), thrombocytopenia (13 [33%]), anaemia (11 [28%]), anorexi

37 tients were neutropenia (22%), anemia (13%), thrombocytopenia (13%), and electrocardiogram QT prolong

38 group), anaemia (142 [42%] vs 68 [40%]), and thrombocytopenia (134 [40%] vs 48 [28%]).

39 were neutropenia (39 [48%] of 81 patients), thrombocytopenia (14 [17%]), and febrile neutropenia (te

40 group and 16 [28%] in the nivolumab group), thrombocytopenia (14 [26%] in the pembrolizumab group an

41 ration (11%), electrolyte abnormality (19%), thrombocytopenia (15%), elevated transaminase levels (7%

42 common grade 3 or worse adverse events were thrombocytopenia (17 [13%] among 132 patients who receiv

43 above were neutropenia (41 [56%] of 73) and thrombocytopenia (17 [23%] of 73).

44 t common grade 3 or more adverse events were thrombocytopenia (18 [41%] of 44 patients), neutropenia

45 ]) in group 1; neutropenia (27 [82%] of 33), thrombocytopenia (18 [55%]) and anaemia (17 [52%]) in gr

46 22 [73%] of 34), neutropenia (21 [70%]), and thrombocytopenia (18 [60%]) in group 1; neutropenia (27

47 1%] of 99 patients in the 3.4 mg/kg cohort), thrombocytopenia (19 [20%] and 33 [33%]), and anaemia (1

48 l, including neutropenia (18 [7%] patients), thrombocytopenia (19 [7%] patients), and anaemia (8 [3%]

49 n and included lymphopenia, neutropenia, and thrombocytopenia (21 [100%] patients for each toxicity);

50 egardless of relationship to treatment, were thrombocytopenia (22 [41%] of 53 patients in the 60 mg/m

51 n group 2; and neutropenia (23 [66%] of 35), thrombocytopenia (22 [63%]), and nausea (17 [49%]) in gr

52 o group), pneumonia (30 [16%] vs nine [9%]), thrombocytopenia (28 [15%] vs 29 [30%]), anaemia (28 [15

53 -4 adverse events were clinically manageable thrombocytopenia (28 [62%] patients) and neutropenia (26

54 The most common were neutropenia (4%), thrombocytopenia (3%), and increased lipase (3%).

55 1-5.65 vs 3.32 log, range 1-5.36; P = .001), thrombocytopenia (3.68 log, range 1-5.65 vs 3.43 log, ra

56 to 4 toxicities included neutropenia (41%), thrombocytopenia (30%), hypertension (15%), febrile neut

57 e 3/4 treatment-emergent adverse events were thrombocytopenia (31%), lymphopenia (24%), anemia (21%),

58 in any group) grade 3-4 adverse events were thrombocytopenia (33 [42%] of 78, 26 [31%] of 83, and 19

59 tinal obstruction (34 [7%] of 463 patients), thrombocytopenia (34 [7%] of 463 patients), and vomiting

60 up), neutropenia (34 [13%] and 20 [8%]), and thrombocytopenia (36 [14%] and 35 [14%]).

61 acute kidney injury, 39% (range, 16-60%) for thrombocytopenia, 36% (range, 29-44%) for hepatic injury

62 ardless of causality were neutropenia (46%), thrombocytopenia (38%), and febrile neutropenia (29%).

63 verse events were febrile neutropenia (42%), thrombocytopenia (38%), and WBC count decreased (34%).

64 ted AST (50%), and constipation, nausea, and thrombocytopenia (42% each).

65 buminemia (55%), peripheral edema (51%), and thrombocytopenia (49%).

66 anaemia (7 [15%] of 48 vs 9 [18%] of 49) and thrombocytopenia (5 [10%] vs 6 [12%]), and hypertension

67 ), neutropenia (1.3% vs 0.2%, P < .001), and thrombocytopenia (5.5% vs 2.7%, P < .001) compared with

68 ine monotherapy, CDAR led to brief grade 3/4 thrombocytopenia (59% v 9%; P < .0001) and platelet tran

69 emergent adverse events were anemia (64.8%), thrombocytopenia (62.0%), hypokalemia (49.3%), neutropen

70 [2%] of 121 patients in the placebo group), thrombocytopenia (67 [27%] vs three [2%]), and leucopeni

71 y), neutropenia (32% and 30%, respectively), thrombocytopenia (7% and 11%, respectively), asthenia (1

72 dverse events were hyperbilirubinemia (10%), thrombocytopenia (7%), and IDH differentiation syndrome

73 including neutropenia (362 [33%] patients), thrombocytopenia (72 [7%] patients), and anaemia (42 [4%

74 nia), infections (86 [31%] vs 48 [18%]), and thrombocytopenia (76 [27%] vs 79 [29%]).

75 f patients, most commonly neutropenia (79%), thrombocytopenia (76%), and anemia (43%).

76 most frequent grade 3-4 adverse events were thrombocytopenia (77 [39%] of 195 patients in the seline

77 es were neutropenia (96%), leukopenia (84%), thrombocytopenia (82%), anemia (74%), and fatigue (72%);

78 nia, anemia, 98% each; neutropenia, 93%; and thrombocytopenia, 84%).

79 were anaemia (113 [24%] of 463 patients) and thrombocytopenia (95 [21%] of 463 patients).

80 Thrombocytopenia, a reduction in circulating platelet co

81 The combined phenotype of thrombocytopenia accompanied by intellectual disability

82 gic toxicity (5 cases of leukopenia and 2 of thrombocytopenia, all grade 1 or 2) and clinical side ef

83 experienced grade 4 neutropenia with grade 4 thrombocytopenia also occurring in three of these patien

84 mg twice a day with at least one of grade 3 thrombocytopenia, anaemia, or bleeding at grade 3 or wor

85 a constellation of symptoms/signs including thrombocytopenia, anasarca, fever, reticulin fibrosis/re

86 6-blockade refractory iMCD patients with the thrombocytopenia, anasarca, fever/elevated C-reactive pr

87 ons in PTPRJ that caused autosomal-recessive thrombocytopenia and a bleeding disorder in 2 siblings.

88 ously unidentified mechanism of DENV-induced thrombocytopenia and a potential therapeutic target.

89 Thrombocytopenia and anemia were common, but product ava

90 We studied 2 unrelated patients with immune thrombocytopenia and autoimmune hemolytic anemia in the

91 Thrombocytopenia and bleeding (both grade 3/4 but fully

92 ral, clinicians should not routinely correct thrombocytopenia and coagulopathy before low-risk therap

93 ome is a triad of progressive renal failure, thrombocytopenia and haemolytic anaemia which is a condi

94 Finally, IdeS prevented thrombocytopenia and hypercoagulability induced by 5B9 w

95 tients with cirrhosis exhibit multifactorial thrombocytopenia and in vitro thrombocytopathy, counterb

96 Thrombocytopenia and injection-site reactions were commo

97 Care for individuals with ETV6-related thrombocytopenia and leukemia predisposition includes ge

98 tions in ETV6 are responsible for a familial thrombocytopenia and leukemia predisposition syndrome.

99 echanisms by which ETV6 dysfunction promotes thrombocytopenia and leukemia remain unclear.

100 ection and was associated with mild cases of thrombocytopenia and neutropenia, none of which was grad

101 Even though the degree of thrombocytopenia and platelet activation were similar be

102 t 18 years, with primary or secondary immune thrombocytopenia and platelet counts less than 100 x 10(

103 Baseline thrombocytopenia and platelet decrease following renal r

104 s a risk factor for anemia, neutropenia, and thrombocytopenia and requires ongoing attention and moni

105 h no sign of cirrhosis, including absence of thrombocytopenia and signs of advanced liver disease on

106 ot absent Scl These Pf4Sclc-KO mice had mild thrombocytopenia and subtle defects in platelet aggregat

107 or neutropenia, 15 (55%) versus two (9%) for thrombocytopenia, and 14 (52%) versus eight (35%) for an

108 tropenia, 19 (10%) had anaemia, two (1%) had thrombocytopenia, and 56 (31%) had an infection.

109 1%) had laboratory-confirmed heparin-induced thrombocytopenia, and all of them developed cannula-asso

110 ted in more frequent grade 4 neutropenia and thrombocytopenia, and did not affect survival.

111 Lymphopenia, thrombocytopenia, and elevation in inflammatory markers,

112 epatobiliary dysfunction, renal dysfunction, thrombocytopenia, and hyperlactatemia.

113 troke, renal failure, myocardial infarction, thrombocytopenia, and other end-organ damage.

114 mm Hg), anemia requiring blood transfusions, thrombocytopenia, and pneumonia.

115 DIC, clinically relevant thrombocytopenia, and reduced fibrinogen were rare and w

116 neutropenia aOR, 6.3 (95% CI, 2.0-19.6); and thrombocytopenia aOR, 2.7 (95% CI, 1.8-4.2).

117 ), leukocytosis (aOR 2.35, 95%CI 1.35-4.11), thrombocytopenia (aOR 1.01, 95%CI 1.00-1.01, increase pe

118 of ITs, nearly 50% of patients with familial thrombocytopenia are affected with forms of unknown orig

119 Patients with immune thrombocytopenia are at risk of bleeding during surgery,

120 Both the prevalence and incidence of thrombocytopenia are high in septic shock.

121 ever, the mechanisms leading to DENV-induced thrombocytopenia are unknown.

122 h as TpoR/MPL R102P, which causes congenital thrombocytopenia, are rescued for traffic and function b

123 reduced number of thrombocytes in the blood (thrombocytopenia) as well as symptoms of gastrointestina

124 iMCD can be further subclassified into iMCD-thrombocytopenia, ascites, reticulin fibrosis, renal dys

125 ion of phagocytes responsible for anemia and thrombocytopenia associated with inflammation and infect

126 Therapeutic plasma exchange use in thrombocytopenia-associated multiple organ failure was a

127 ty, and biochemical markers in children with thrombocytopenia-associated multiple organ failure who r

128 an NEC within 24 h, and these mice developed thrombocytopenia at 12 to 15 h.

129 Of 980 adults, 165 patients (16.8%) had thrombocytopenia at ICU admission (prevalent), whereas 2

130 Predictor variables were thrombocytopenia at initiation of renal replacement ther

131 se manifestations include episodes of immune thrombocytopenia, autoimmune hemolytic anemia, or neutro

132 entified a past history of liver disease and thrombocytopenia before conditioning therapy as dominant

133 ulcers, rehospitalization, critical illness, thrombocytopenia, blood dyscrasias, hepatic disease, ren

134 e infrequent because of risk associated with thrombocytopenia, but in 6 patients, there were varying

135 We determined that selinexor causes thrombocytopenia by blocking thrombopoietin (TPO) signal

136 PTPRJ mutations presented as a nonsyndromic thrombocytopenia characterized by spontaneous bleeding,

137 Severe thrombocytopenia, characterized by dysplastic megakaryoc

138 Chemotherapy-induced thrombocytopenia (CIT) leads to delay or reduction in ca

139 nd symptoms of the liver cirrhosis occurred (thrombocytopenia, collateral venous circulation, first d

140 as not an independent predictor of worsening thrombocytopenia compared with those treated with interm

141 ss than 34 weeks of gestation in whom severe thrombocytopenia developed to receive a platelet transfu

142 gometry was assessed against heparin-induced thrombocytopenia diagnosis (clinical picture in favor, s

143 Using heparin-induced thrombocytopenia diagnosis as reference, heparin-induced

144 metry performed very well in heparin-induced thrombocytopenia diagnosis in ICU patients and agreed wi

145 perform functional assay for heparin-induced thrombocytopenia diagnosis in ICU patients, known as "he

146 Heparin-induced thrombocytopenia diagnosis was retained in 12 patients (

147 y improve the specificity of heparin-induced thrombocytopenia diagnosis, but they are not readily ava

148 h the gold standard test for heparin-induced thrombocytopenia diagnosis, the serotonin release assay.

149 n (prevalent), whereas 271 (27.7%) developed thrombocytopenia during ICU admission (incident).

150 with acute myeloid leukaemia frequently have thrombocytopenia during induction chemotherapy.

151 sed by mutations in the WAS gene, leading to thrombocytopenia, eczema, recurrent infections, autoimmu

152 most common grade 3 or 4 adverse events were thrombocytopenia (eight [32%] of 25 patients) and hypona

153 3 patients were neutropenia (nine [69%]) and thrombocytopenia (eight [62%]).

154 The virus may cause thrombocytopenia either by destroying the platelets or b

155 tic microangiopathy together with hematuria, thrombocytopenia, elevated creatinine, and evidence of h

156 verse events in NCT02042989 included anemia, thrombocytopenia, fatigue, nausea, vomiting, and diarrhe

157 L-10 (hIL-10) has been limited by anemia and thrombocytopenia following systemic injection, side effe

158 18%] of 148 patients; no grade 4 events) and thrombocytopenia (grade 3, 13 [9%] of 148 patients; grad

159 grade 4 thrombocytopenia, prolonged grade 3 thrombocytopenia, grade 4 neutropenia, and pleural effus

160 Heparin-induced thrombocytopenia had no effect on mortality.

161 on (eg, as measured with plasma D-dimer) and thrombocytopenia have emerged as prognostic markers in C

162 atelets and microthrombosis, which result in thrombocytopenia, hemolytic anemia, and tissue ischemia.

163 factor and platelets, which account for the thrombocytopenia, hemolytic anemia, schistocytes, and ti

164 vel diagnostic algorithm for heparin-induced thrombocytopenia (HIT) based on the 4Ts score and 2 rapi

165 Heparin-induced thrombocytopenia (HIT) is a prothrombotic disorder initi

166 Heparin-induced thrombocytopenia (HIT) is a prothrombotic disorder media

167 Heparin-induced thrombocytopenia (HIT) is caused by platelet-activating

168 stic evaluation of suspected heparin-induced thrombocytopenia (HIT) is critical for guiding initial p

169 Heparin-induced thrombocytopenia (HIT) is due to immunoglobulin G (IgG)

170 markers for the diagnosis of heparin-induced thrombocytopenia (HIT), a difficult-to-diagnose immune-r

171 icated in the development of heparin-induced thrombocytopenia (HIT), a potentially fatal immune disor

172 t factor 4 (PF4) involved in heparin-induced thrombocytopenia (HIT), beta-2-glycoprotein-1 implicated

173 liver disease (e.g., elevated transaminases, thrombocytopenia), human immunodeficiency virus-positive

174 ukopenia in 13%, lymphocytopenia in 24%, and thrombocytopenia in 17%.

175 toxic effects were haematological, including thrombocytopenia in 63 (74%) patients, neutropenia in 53

176 61 (60%) patients, anaemia in 101 (37%), and thrombocytopenia in 72 (27%).

177 platelet activation in vitro and to restore thrombocytopenia in DENV-infected MC-deficient mice.

178 The frequency of heparin-induced thrombocytopenia in extracorporeal membrane oxygenation

179 ranscription factor associated with dominant thrombocytopenia in humans.

180 during DENV infection effectively prevented thrombocytopenia in mice.

181 hold less than 1 to rule out heparin-induced thrombocytopenia in patients on extracorporeal membrane

182 ) or without (89/279, 32.2%) heparin-induced thrombocytopenia in patients on extracorporeal membrane

183 difference in prevalence of heparin-induced thrombocytopenia in patients on venovenous-extracorporea

184 ability Score in identifying heparin-induced thrombocytopenia in patients post cardiopulmonary bypass

185 Baseline thrombocytopenia in patients requiring renal replacement

186 development, as reflected in the presence of thrombocytopenia in the context of congenital disorders

187 iHPCs were responsible for anemia and thrombocytopenia in TLR7-overexpressing mice, which have

188 gher were anemia (in 31.0% of the patients), thrombocytopenia (in 28.7%), and neutropenia (in 12.8%).

189 n 78% of the patients), anemia (in 43%), and thrombocytopenia (in 38%).

190 ), leukopenia (in 58%), anemia (in 45%), and thrombocytopenia (in 45%).

191 most common adverse events up to day 28 were thrombocytopenia (in 50 of 152 patients [33%] in the rux

192 Thrombocytopenia increased in cardiopulmonary bypass pat

193 Heparin-induced thrombocytopenia is a recognized concern in patients on

194 Heparin-induced thrombocytopenia is a relatively common drug-induced imm

195 Thrombocytopenia is a serious issue for all patients wit

196 Thrombocytopenia is almost completely penetrant and is u

197 Thrombocytopenia is already common at extracorporeal mem

198 Thrombocytopenia is associated with a reduction in the o

199 In septic shock, thrombocytopenia is associated with increased length of

200 Here, we show that thrombocytopenia is caused by serotonin derived from mas

201 Thrombocytopenia is common in critically ill patients wi

202 Heparin-induced thrombocytopenia is more frequent in both venovenous- an

203 nes, but platelet recovery from severe acute thrombocytopenia is slower in RGS18-/- and RGS10-/-18-/-

204 Management of immune thrombocytopenia (ITP) during pregnancy can be challengi

205 approved for the treatment of chronic immune thrombocytopenia (ITP) in patients without adequate resp

206 Immune thrombocytopenia (ITP) is an acquired bleeding disorder

207 ion of life-threatening hemorrhage in immune thrombocytopenia (ITP) must be balanced against adverse

208 Immune thrombocytopenia (ITP) secondary to chronic lymphoprolif

209 al anti-D is a first-line therapy for immune thrombocytopenia (ITP).

210 hanisms involved in antibody-mediated immune thrombocytopenia (ITP).

211 Inherited thrombocytopenias (ITs) are a heterogeneous group of dis

212 Thrombocytopenia led to bleeding events of grade 3 or hi

213 nalysis showed that higher the percentage of thrombocytopenia less than 100 G/L during extracorporeal

214 However, the on-target and dose-limiting thrombocytopenia limits the use of BCL-X(L) inhibitors,

215 ffering from severe respiratory distress and thrombocytopenia living with a family with several membe

216 ng both Adamts13 (-/-) and cfh (W/R) exhibit thrombocytopenia, low haptoglobin, increased fragmentati

217 > 1.2), hypofibrinogenemia (< 2.0 g/L), and thrombocytopenia (< 100 x10/L), univariate regression mo

218 ed Hippo kinase loss to induce splenomegaly, thrombocytopenia, megakaryocytic dysplasia, and a propen

219 ymptomatic (eg, cardiac failure n = 39, 31%; thrombocytopenia n = 12, 10%).Increased hepatic artery v

220 nt: grade 4 neutropenia (n = 2 patients) and thrombocytopenia (n = 1), and grade 1 (10%) and grade 2

221 Dose limiting toxicity (DLT) is grade 4 thrombocytopenia (n = 2).

222 s; the most common were neutropenia (n = 9), thrombocytopenia (n = 3), and peripheral neuropathy (n =

223 se events were anaemia (n=2), fatigue (n=1), thrombocytopenia (n=1), hypomagnesaemia (n=1), diarrhoea

224 he most common grade 3-4 adverse events were thrombocytopenia (n=58), neutropenia (n=31), anaemia (n=

225 e platinum-etoposide group (pancytopenia and thrombocytopenia [n=1 each]).

226 optical density thresholds, heparin-induced thrombocytopenia negative was defined as an optical dens

227 aise, anorexia, gastrointestinal complaints, thrombocytopenia, neutropenia, and aminotransferase elev

228 Thrombocytopenia occurred in 73% of the patients (grade

229 Thrombocytopenia occurred on >=1 day in 58% of patients

230 Incident thrombocytopenia occurs early in septic shock, and plate

231 sts that were suggestive of disease (such as thrombocytopenia or hepatic or renal dysfunction).

232 on in solid tumors or chronic, stable severe thrombocytopenia) or that were addressed partially (inva

233 and Cox proportional hazard model evaluating thrombocytopenia over time.

234 al assay that could decrease heparin-induced thrombocytopenia overdiagnosis in the ICU setting.

235 13q (P = .006), splenomegaly (P = .02), and thrombocytopenia (P = .004), whereas PC-like WM harbored

236 ith significant hypoalbuminemia (P < .0027), thrombocytopenia (P = .0045), and elevated IL-10 levels

237 PegIFN-induced thrombocytopenia (P = .299 vs controls) and neutropenia

238 ividuals with ichthyosis, failure to thrive, thrombocytopenia, photophobia, and progressive hearing l

239 The Platelets for Neonatal Thrombocytopenia (PlaNeT-2) trial reported an unexpected

240 demand and supply of blood for patients with thrombocytopenia (platelet count <=50 x 10(9)/L), anemia

241 han 60 years, anemia (hemoglobin < 10 g/dL), thrombocytopenia (platelets < 100 x 10(9)/L), presence o

242 al density less than 1.0 and heparin-induced thrombocytopenia positive as an optical density greater

243 imary outcome: age, vasopressor requirement, thrombocytopenia, preexisting kidney disease, failed ven

244 Severe thrombocytopenia produced by two distinct methods caused

245 DLTs included grade 4 thrombocytopenia, prolonged grade 3 thrombocytopenia, gr

246 ases, including myasthenia gravis and immune thrombocytopenia, provides further evidence that IgG is

247 rrets (>=4 years of age) demonstrated severe thrombocytopenia, reduced white blood cell counts and hi

248 Overdiagnosis of heparin-induced thrombocytopenia remains an unresolved issue in the ICU

249 he clinical manifestations (microangiopathy, thrombocytopenia, renal injury, and thrombophilia) of CO

250 affecting other organ systems (proteinuria, thrombocytopenia, renal insufficiency, liver involvement

251 s with confirmed NEC develop moderate-severe thrombocytopenia requiring one or more platelet transfus

252 for proplatelet formation, thus resulting in thrombocytopenia (see figure).

253 enia (30 [29%]), neutropenia (48 [46%]), and thrombocytopenia (seven [7%]).

254 es dengue fever in humans, which can lead to thrombocytopenia showing a marked reduction in platelet

255 [30%]), febrile neutropenia (12 [18%]), and thrombocytopenia (six [9%]).

256 ion to Chk and Csk ameliorates the extent of thrombocytopenia, suggesting targeting it may have thera

257 Severe fever with thrombocytopenia syndrome (SFTS) is an emerging disease

258 sting minigenome system of severe fever with thrombocytopenia syndrome (SFTS) phlebovirus (SFTSV) to

259 Severe fever with thrombocytopenia syndrome phlebovirus (SFTSV), listed in

260 Severe fever with thrombocytopenia syndrome phlebovirus (SFTSV), listed in

261 Although the incidence of severe fever with thrombocytopenia syndrome virus (SFTSV) infection has in

262 tructural protein (NSs) of severe fever with thrombocytopenia syndrome virus (SFTSV) interacts with a

263 12-30% fatality rates with a characteristic thrombocytopenia syndrome.

264 retest Probability Score and heparin-induced thrombocytopenia testing results were collected prospect

265 Among patients with incident thrombocytopenia, the median time from ICU admission to

266 fficacy outcomes, with a higher incidence of thrombocytopenia, the most frequent toxic effect, than t

267 Among preterm infants with severe thrombocytopenia, those randomly assigned to receive pla

268 oup), asthenia (six [2%] and four [3%]), and thrombocytopenia (three [1%] and ten [7%]).

269 ted grade 3 or worse adverse events included thrombocytopenia (three [3%]), neutropenia (three [3%]),

270 rders) and history of coagulation disorders (thrombocytopenia, thrombosis and hemorrhage) are risk fa

271 sed our neonatal murine model of NEC-related thrombocytopenia to investigate mechanisms of platelet d

272 Here, we used a mouse model of acute thrombocytopenia to investigate the cross talk between H

273 ong survivors, the median time from incident thrombocytopenia to platelet recovery was 6 days (interq

274 ts in the single-agent cohort, most commonly thrombocytopenia (two [15%]).

275 erase concentration (two [7%] patients), and thrombocytopenia (two [7%] patients).

276 entially functional variant segregating with thrombocytopenia under a recessive model: GALE p.R51W (c

277 ent adverse events with DARA-MD 1200 mg were thrombocytopenia, upper respiratory tract infection, ins

278 we tested 2 mouse models of immune-mediated thrombocytopenia using the rat anti-mouse GPIbalpha mono

279 penia, the median time from ICU admission to thrombocytopenia was 2 days (interquartile range, 1-3 d)

280 iated with increased mortality, and baseline thrombocytopenia was associated with decreased rates of

281 In a propensity-matched analysis, thrombocytopenia was associated with increased durations

282 ction required more than 4 h to emerge after thrombocytopenia was established, reverting to normal as

283 ability Score in identifying heparin-induced thrombocytopenia was lower in extracorporeal membrane ox

284 Importantly, at an equivalent dose in rats, thrombocytopenia was mitigated.

285 Thrombocytopenia was present in 7875 patients (9%), high

286 an adjusted Cox proportional hazards model, thrombocytopenia was significantly associated with both

287 Thrombocytopenia was similarly detected using the calcul

288 ncing of 2 siblings with autosomal-recessive thrombocytopenia, we identified biallelic loss-of-functi

289 To identify novel causes of hereditary thrombocytopenia, we performed a genetic association ana

290 Myelofibrosis, panleukopenia, anemia, and thrombocytopenia were ameliorated, the wart burden and f

291 llary leak syndrome; hepatic dysfunction and thrombocytopenia were common.

292 Moderate and severe thrombocytopenia were more common in extracorporeal memb

293 Grade >= 3 anemia and thrombocytopenia were observed in 34% and 14% of patient

294 , and March 7, 2019, 92 patients with immune thrombocytopenia were screened, of whom 74 (80%) were ra

295 Neutropenia and thrombocytopenia were the most frequent adverse events,

296 sical VOD patients presented with refractory thrombocytopenia, while less than half met EBMT criteria

297 Dengue patients with thrombocytopenia who were older or presented earlier and

298 inhibitory phosphorylation of SFKs leads to thrombocytopenia, with Csk being the dominant inhibitor

299 ns in objectively ruling out heparin-induced thrombocytopenia without sending a confirmatory serotoni

300 Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia (XLT) because it causes severe and life